Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Vernalis (LSE:VER; VNLS) granted ENDP exclusive North American sales and marketing rights for migraine drug Frova frovatriptan. ENDP also
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury